A Service For Professionals Saturday, October 21, 2017
Contact (202) 540-8337
Conferences & Trade Shows Today
A Service For Professionals Saturday, October 21, 2017 11614 Sources 411,093,432 Articles 3,134,516 Readers
Contact (202) 540-8337

Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that the company will provide a corporate overview and participate in a fireside chat, led by Joanna Horobin, M.B. Ch.B., Idera’s Chief Medical Officer at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 9:45 a.m. Eastern Time at the Le Parker Meridien Hotel in New York City.

/EIN News/ -- Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com.  Archived versions will also be available on the Company’s website after the event for 90 days. 

About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

Investor and Media Contact
                    Robert Doody
                    VP, IR & Corporate Communications
                    617-679-5515 (office)
                    484‐639‐7235 (mobile)
                    rdoody@iderapharma.com

Primary Logo

Powered by EIN News